Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu

Ganesh Kumar Anbazhagan, Sridharan Krishnamoorthy, Thirunalasundari Thiyagarajan

AIM: To determine the seroprevalence of hepatitis C virus (HCV) and its co-infection with hepatitis B virus (HBV), hepatitis delta agent (HDV) and human immunodeficiency virus (HIV) among liver disease patients of south Tamil Nadu.

METHODS: A total of 1012 samples comprising 512 clinically diagnosed cases of liver disease patients and 500 apparently healthy age and sex matched individuals were screened for Hepatitis C virus (anti HCV and HCV RNA), Hepatitis B virus (HBsAg), Hepatitis delta agent (anti HDV) and Human immunodeficiency virus (antibodies to HIV-1 and HIV-2) using commercially available enzyme linked immunosorbent assay kits. HCV RNA was detected by RT-PCR. Liver function tests like ALT, AST, GGT, ALP, bilirubin and albumin were also studied.

RESULTS: The seroprevalence of HCV was found to be 5.6% among liver disease patients by ELISA. 27/512, 49/512 and 12/512 patients were positive for HIV, HBV & HDV respectively. Co-infection of HCV & HBV was found in 8 patients, with 6 for HCV & HIV and 4 for HCV, HBV & HIV co-infections. Sex-wise analysis showed that HIV, HCV & HBV and HCV & HIV co-infection was high among females whereas for HBV it was high in males. The mean ALT and AST in HCV positive cases were 42.1 ± 8.3 and 49 ± 10.1. In people co-infected with HCV & HBV or HCV & HIV or HCV, HBV & HIV the mean ALT of 58.0 ± 3.16, 56.78 ± 4.40 and 64.37 ± 4.01 respectively.

CONCLUSION: We strongly recommend routine test of the blood for HCV in addition to HBV and HIV. We also recommend individualized counseling to identify those at risk and testing for those who want it. Improved surveillance and periodic epidemiological studies will have to be undertaken to monitor and prevent these blood-borne viruses.

© 2010 Baishideng. All rights reserved.

Key words: Hepatitis C virus; Hepatitis B virus; Human immunodeficiency virus; Co-infection; Liver function test

Peer reviewer: Eva Herrmann, Professor, Department of Internal Medicine, Biomathematics Saarland University, Faculty of Medicine, Kirrberger Str., 66421 Homburg/Saar, Germany

Anbazhagan GK, Krishnamoorthy S, Thiyagarajan T. Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. World J Hepatol 2010; 2(1): 42-48 Available from: URL: http://www.wjgnet.com/1948-5182/full/v2/i1/42.htm DOI: http://dx.doi.org/10.4254/wjh.v2.i1.42
INTRODUCTION

Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the world\(^1\). HCV belongs to the family **flaviviridae** and the genus **hepacivirus**. It often causes lifelong persistent infection\(^2\). The prevalence of HCV infection worldwide has been estimated to be about 3% with 170 million people affected by HCV\(^3\). Meanwhile two billion people have been infected with hepatitis B virus (HBV). Of these, 360 million have chronic infection and 600000 die each year due to HBV infection and related liver diseases\(^4\). HBV and HCV infections account for a substantial proportion of liver diseases worldwide. The majority of those with chronic HBV and/or HCV infection will develop complications i.e. 15%-40% may develop cirrhosis, liver failure and or hepatocellular carcinoma\(^5\). The exact number of patients infected with both HCV and HBV world wide is unknown\(^6\). It has been estimated that over the next 20 years, the proportion of HBV/HCV infected patients with cirrhosis will increase from 16% to 32% and that other complications will also increase dramatically including hepatic decompensation (increasing by 106%), HCC (increasing by 81%) and liver related deaths (increasing by 180%)\(^7\). In addition, prevalence of human immunodeficiency virus (HIV) is increasing everyday and it has become a disaster for humankind in certain areas. HIV accounted for 38.6 million infections worldwide by the end of 2005\(^8\). These three viruses (HCV, HBV and HIV) have similar routes of transmission, namely through blood and blood products. Sharing of needles to inject drugs and sexual activity enables the co-infection of these viruses and thereby makes co-infection or super infection a common event\(^9\). End stage liver disease is currently a major concern among HIV positive individuals due to co-infection with hepatotropic viruses\(^10,11\). HIV infected patients with multiple hepatitis virus infections have a higher rate of liver related morbidity and mortality than patients with HIV infection alone or with a single hepatitis virus infection. The degree of immunodepression is an important factor in liver disease progression\(^12\). Current estimations indicate that approximately 1.8% to 2.5% of Indian population is presently infected by HCV\(^13\). The prevalence as well as the significance of HCV infection varies considerably from country to country, probably because of cultural factors and social habits that influence HCV transmission. A community based Indian study on HCV indicated a seroprevalence of 0.87% and that the rate reportedly increased from children < 10 years to 1.85% among subjects > 60 years of age\(^14\). Knowledge and awareness of HCV infection have been obtained from seroprevalence studies carried out in blood donors and hemodialysis patients from large cities\(^15-17\). Reports on the prevalence of HCV infection in the Indian subcontinent is scarce. Hence, this study was conducted to investigate the seroprevalence of HCV and its co-infection with HBV and HIV in liver disease patients in South Tamil Nadu.

MATERIALS AND METHODS

Study samples

The study was performed in 512 clinically diagnosed cases of liver disease patients and 500 apparently healthy age and sex matched controls. All the liver diseases and control samples were diagnosed and given by the Gastroenterologist based on signs, symptoms and examination. Blood samples were collected from them, serum was separated and stored at -20°C until use. Among the liver disease patients clinical conditions including acute liver disease, chronic liver disease and cirrhosis were also diagnosed by the Gastroenterologist.

Serology

The blood samples were screened for markers of various hepatitis viruses and HIV by using third generation ELISA kits. Hepatitis B surface antigen (HBsAg) was screened by Hepalis, supplied by M/s. J. Mitra and Co Pvt. Ltd, India; Hepatitis B envelop antigen (HBeAg) and antibody to envelop antigen (anti-HBe) using ELISA kits supplied by M/s. Biorad laboratories, USA.; Antibodies to HCV, HDV and HIV were screened by using Microlisa kits supplied by M/s. J. Mitra and Co Pvt. Ltd, India. All reactive analyses were repeated twice.

Biochemistry

Liver function tests studied were alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), serum alkaline phosphatase (SAP), bilirubin and albumin. The results were correlated with serological findings. The upper limits of normal for various tests were ALT 0-65 IU/L, AST 5-40 IU/L, GGT 0-61 IU/L, SAP 20-140 KA, Bilirubin Total 0.3 to 1.9 mg%, Direct bilirubin: 0 to 0.3 mg%, Indirect bilirubin 0.1-1.0 mg% and Albumin 35-50 gms%.

Molecular diagnosis of HCV

For the detection of the HCV genome, RNA was extracted from the samples and was subjected to reverse transcriptase polymerase chain reaction (RT-PCR). This was carried out for the constant HCV 5’ untranslated region (5’UTR).

Statistical analysis

Statistical package for social sciences (SPSS, version 17.0) software was used for analyzing the data. Statistical tests used to find the significance were $\chi^2$ for association of attributes and $t$-test for difference in the mean for independent samples.

RESULTS

Among the 512 liver disease patients investigated, 281 were male and 231 were female. Overall 29 (5.6%) were
positive for HCV. This positivity was either for anti-HCV by ELISA, for HCV RNA by RT-PCR or for both. Results based on other viral infection revealed 27 (5.2%) for HIV, 49 (9.5%) for HBsAg, and 12 (23%) for HDV (Table 1). Table 2 shows the incidence of blood borne viral infection and co-infection among liver disease patients. Co-infection of HCV & HBV was found in 8 patients, with 6 for HCV & HIV and 4 for HCV, HBV & HIV co-infections. In addition, clinical conditions of all viral infections and co-infections were significantly ($P < 0.01$) associated with liver disease (Table 3). Table 4 gives the age-wise distribution of patients with different kinds of viral infections. The total viral positivity was insignificant in various age groups ($P > 0.05$). Among the viral positive cases, HBV was most prevalent followed by other viral infections and co-infections whilst the rest were insignificant ($P < 0.05$) (Tables 5 and 6). The results of liver function tests in HCV infected and co-infected patients are presented in Table 7. All the parameters tested were found to increase significantly ($P < 0.05$) when compared to controls. Data collected based on risk factor for HCV seroconversion reveals, 47.6% of the patients had blood transfusion, 6 had surgical intervention (14.2%), 5 were intravenous drug users (11.9%) and 11 (26%) had unknown causes. Blood transfusion (65%) was observed as the predominant risk factors in the co-infected patients.

**DISCUSSION**

HIV, HBV and HCV are the three most common chronic blood borne viral infections documented worldwide[18]. Epidemiological studies of blood-borne viral disease such as HCV, HBV and HIV are important for revealing the risk groups and risk factors for these infections. Screening these groups of viruses helps us to solve difficulties in collecting information among healthy populations[19].

India has the second highest number of people living with HIV infection[20]. Co-infection of hepatotropic viruses with HIV infection reportedly leads to massive impairment of cell mediated responses and enhances

---

**Table 1** Incidence of blood borne viral infection (HCV, HBV, HDV and HIV) among liver disease patients

| Category               | Total number tested | Gender       | Male | Female | HCV, HBV, HDV and HIV positive |
|------------------------|---------------------|--------------|------|--------|---------------------------------|
|                        |                     |              |      |        | HCV | HBV | HDV | HIV |
| Liver disease          | 512                 |              | 281  | 231    | 29 (5.6) | 49 (9.5) | 12 (2.3) | 27 (5.2) |
| Control                | 500                 |              | 250  | 250    | -    | 7 (1.4) |    | -   |
| Total                  | 1012                |              | 531  | 481    | 29   | -   | 7 (1.4) | 12 (2.3) |

**Table 2** Incidence of blood borne viral infection and co-infection among liver disease patients

| Category               | Clinical condition                      | Gender       | Male | Female | Total |
|------------------------|-----------------------------------------|--------------|------|--------|-------|
|                        |                                        |              |      |        |       |
|                        |                                        | Virus positive | Virus negative | Total | Virus positive | Virus negative | Total |
| Liver disease          | Acute liver disease                     | 22            | 55   | 77    | 12   | 38   | 50   | 127  |
|                        | Chronic liver disease                   | 45            | 34   | 79    | 26   | 51   | 77   | 156  |
|                        | Cirrhosis                               | 14            | 31   | 45    | 7    | 33   | 40   | 85   |
|                        | Others                                  | 16            | 64   | 80    | 2    | 62   | 64   | 144  |
|                        | Total                                   | 97            | 184  | 281   | 47   | 184  | 231  | 512  |
| Control                | Without any signs or symptoms           | 4             | 246  | 250   | 3    | 247  | 250  | 500   |
| Total                  |                                        | 101           | 430  | 531   | 50   | 431  | 481  | 1012 |

$\chi^2 = 12.598$ for $df = 1$, $P < 0.01$ for gender vs viral infection. $\chi^2 = 41.33$ for $df = 3$, $P < 0.01$ for clinical condition vs viral infection.

**Table 3** Clinical condition vs blood-borne viral infection

| Clinical condition       | Different viral infection positive | Total virus positive | Total number tested |
|-------------------------|-----------------------------------|---------------------|---------------------|
|                         | HCV | HBV | HIV | HDV | HCV and HBV | HCV and HIV | HBV and HIV | HCV, HBV and HIV |
| Acute liver disease     | -   | 19  | 10  | 4   | -           | -           | -           | -                   |
| Chronic liver disease   | 13  | 11  | 17  | 8   | 6           | 6           | 6           | 4                   |
|                        |    |    |    |    | 6           | 6           | 6           | 4                   |
|                        |    |    |    |    | 6           | 6           | 6           | 6                   |
|                        |    |    |    |    | 2           | 1           | 1           | 2                   |
|                        |    |    |    |    | 1           | 1           | 1           | 1                   |
|                        |    |    |    |    | 1           | 1           | 1           | 1                   |
|                        |    |    |    |    | 20          | 20          | 20          | 20                  |
| Others                 | 4   | 14  | -   | -   | -           | -           | -           | -                   |
|                        | 4   | 14  | -   | -   | -           | -           | -           | -                   |
|                        | 4   | 14  | -   | -   | -           | -           | -           | -                   |
| Total                  | 29  | 49  | 27  | 12  | 8           | 6           | 9           | 4                   |

$\chi^2 = 41.631$ for $df = 3$, $P < 0.01$. $\chi^2$ is calculated for clinical condition against total viral infection.
the kinetics of hepatotropic viral replication\textsuperscript{21-24}. The prevalence of HCV in this study is 8.2% in liver disease patients. A study conducted by Chowdhury \textit{et al.}\textsuperscript{25} (2003) from eastern India showed a prevalence of 0.87%, which is ten times less than that observed in the present study. That study predominantly comprised blood-transfusion-acquired HCV infections rather than other modes of transmission. Age-wise analysis in the present study found HCV to be high among individuals belonging to the 41-50 years (28.5%) age group. HCV infections usually progress slowly to terminal liver disease\textsuperscript{20,26}. It is, therefore, possible to estimate the impact that the disease may have in the future based on the knowledge of its previous incidence. It is also feasible to estimate the burden of late complications associated directly with the presence of chronic liver disease\textsuperscript{21}.

It was observed that males were more susceptible to HCV than female among the study population. This concurs with a previous report that male subjects were at a higher risk of developing HBV infection than females\textsuperscript{26-29}.

Out of the 512 liver disease patients tested 49 (9.5%) were positive for HBsAg. Similar results were obtained in an earlier study conducted on chronic liver disease in India\textsuperscript{30}. A multicenter study in Italy showed that the subjects with dual HBV and HCV infection were more likely to be older than 42 years\textsuperscript{31}. Similar results (1.5%) were found in the current study.

Sud \textit{et al.}\textsuperscript{20} (2001) have reported 33.8% prevalence of HBV co-infection in HIV positive patients. Although the effect of HBV infection on HIV is uncertain, HIV appears to have marked influence on the natural history of HBV infection. Although HIV shares a common route of infection with HBV and HCV, its sexual transmission is known to be relatively efficient whereas the sexual transmission of HCV appears to be significantly less efficient than for HIV. Although detailed reports have documented HCV, HBV and HIV co-infection worldwide, only a few reports have been published regarding co-infection in India. Kumar \textit{et al.}\textsuperscript{32} (2003) reported 2.9% co-infection of HBV and HIV in patients with liver diseases. The increased viral replication of HBV in AIDS patients indicates that HIV significantly affects the HBV life cycle and the host ability to clear HBV infection. If this is true, more HBV infection and more chronic carriers would be expected as the AIDS epidemic expands in this part of the country. Such a profile would have worrying public health implications\textsuperscript{33}. The frequency of HCV & HIV co-infection in this study (1.9%) is much lower than that reported previously among HCV & HIV co-infections in India\textsuperscript{29,34-38} and higher than from the general Indian population\textsuperscript{39}. In the HIV & HCV co-infected patients, the HCV RNA positivity was found to be higher. These observations were in agreement with previous reports of increased hepatotropic viral replication in immunocompromised subjects\textsuperscript{40,41}. Moderate or severe chronic hepatitis or cirrhosis was more frequent in patients with HBV and HCV co-infections than in patients infected with HBV or with HCV alone. Generally, HCV superinfection can cause a much more severe liver disease in patients with

\[
\chi^2 = 4.689 \text{ for df = 5, } P > 0.05, \chi^2 \text{ is calculated for gender against total viral infection.}
\]

\[
\chi^2 \text{ is calculated for gender vs different category of viral infections; } P < 0.05 \text{ is significant, while } P > 0.05 \text{ is insignificant.}
\]

### Table 4 Different viral infection vs age groups

| Viral infection          | Age group in years | Total |
|-------------------------|--------------------|-------|
|                         | 11-20 | 21-30 | 31-40 | 41-50 | 51-60 | 61 and above |
| HCV positive            | 2     | 6     | 7     | 7     | 4     | 3           |
| HBV positive            | 5     | 19    | 6     | 10    | 7     | 2           |
| HIV positive            | -     | 5     | 4     | 8     | 7     | 3           |
| HDV positive            | -     | 1     | 5     | 6     | -     | -           |
| HCV and HBV positive    | 1     | 2     | 1     | 1     | 2     | 1           |
| HCV and HIV positive    | 1     | 1     | 2     | 1     | -     | 1           |
| HBV and HIV positive    | 1     | 1     | 4     | 2     | -     | 1           |
| HCV, HBV and HIV positive| 1   | -     | 1     | 1     | -     | 1           |
| All virus positive      | 11    | 35    | 30    | 36    | 20    | 12          |
| All virus negative      | 42    | 83    | 82    | 94    | 51    | 16          |
| Total                   | 53    | 118   | 112   | 130   | 71    | 28          |

\[
\chi^2 = 6.89 \text{ for df = 5, } P > 0.05, \chi^2 \text{ is calculated for age against total viral infection.}
\]

### Table 5 Different viral infection vs sex

| Viral infection          | Gender | P value |
|-------------------------|--------|---------|
|                         | Male   | Female  |       |
| HCV positive            | 18     | 11     | 0.423 |
| HCV negative            | 263    | 220    |       |
| HBV positive            | 41     | 8      | 0.001 |
| HBV negative            | 240    | 223    |       |
| HIV positive            | 14     | 13     | 0.745 |
| HIV negative            | 267    | 218    |       |
| HDV positive            | 8      | 4      | 0.406 |
| HDV negative            | 273    | 227    |       |
| HCV and HBV positive    | 5      | 3      | 0.663 |
| HCV and HBV negative    | 276    | 228    |       |
| HCV and HIV positive    | 3      | 3      | 0.809 |
| HCV and HIV negative    | 278    | 228    |       |
| HBV and HIV positive    | 6      | 3      | 0.474 |
| HBV and HIV negative    | 275    | 228    |       |
| HCV, HBV and HIV positive| 2    | 2      | 0.844 |
| HCV, HBV and HIV negative| 279  | 229    |       |

\[
\chi^2 = 6.89 \text{ for df = 5, } P > 0.05, \chi^2 \text{ is calculated for gender vs different category of viral infections; } P < 0.05 \text{ is significant, while } P > 0.05 \text{ is insignificant.}
\]
chronic HBV infection. This lends support to the notion that HBV superinfection may also aggravate the disease severity and increase the risk of fulminant hepatitis. In both HIV positive and negative cohorts, the presence of HBV & HCV, HBV & HDV or triple hepatitis infection was strongly associated with intravenous drug use (IDU). Overall, from 0.4% to more than 50% of HIV patients may carry more than one hepatitis virus [42-47]. The reported co-infection rates of HBV and HCV in HIV patients worldwide have varied, depending on the geographic regions, risk groups and the type of exposure involved [48,49]. Tankhiwale et al [50] (2003) reported 5.6% seroprevalence of HCV and 25.8% HBV in HIV infected patients. These co-infection rates were much higher than that of our findings. Four individuals co-infected with HCV, HBV & HIV had neither surgical intervention, blood transfusion or intravenous drug use, suggesting that sexual intercourse could have been the route of infection.

ACKNOWLEDGMENTS

The authors are grateful to Dr. A Rajathi, Associate Professor, Department of Zoology, Holly Cross College, Tiruchirappalli for helping us in performing the statistical analysis.

COMMENTS

**Background**

Hepatitis C virus (HCV) infection creates a significant burden on health care systems. HCV infection has probably been endemic in many populations for centuries. Despite a declining incidence of new infections, the burden of disease in terms of mortality is expected to increase over the next decade.
The complexity and uncertainty related to the geographic distribution of HCV infection and chronic HCV, determination of the associated risk factors and evaluation of cofactors that accelerate its progression, underscore the difficulties in global prevention and control of HCV. Thus, this study set out to determine the seroprevalence of HCV and its co-infection with other blood-borne hepatitis group of viruses and human immunodeficiency virus.

Research frontiers

As HCV is a silent killer virus, diagnosis, treatment and prevention are very important. Hence the results of this study will, if further explored, benefit the public, health care workers, voluntary blood donors and liver disease patients.

Innovations and breakthroughs

Most earlier workers have studied the seroprevalence of HCV either by enzyme linked immunosorbent assay (Antigen or Antibody) specific for the virus or by RT-PCR (viral genome) alone. In this study the seroprevalence of HCV was evaluated by both the methods. This should help to both modify treatment and prevent infection.

Applications

The identification of a high prevalence of HCV in this study indicates the significance of screening HBV, HCV and HDV in addition to HIV, among liver disease patients. Hence we strongly recommend routine testing for health care workers, voluntary blood donors and others to include HBV, HCV and HDV. We also recommend individualized counseling to identify those at risk as well as testing for those who request it. Improved surveillance and periodic epidemiologic studies will have to be undertaken to monitor and prevent the spread of virulent and interferon-resistant strains. Given the current incidence and prevalence data cited above, HCV infection and its co-infection is expected to remain a problem. Further research in the virology, epidemiology, treatment and prevention of blood-borne viral infection is essential if better outcomes to be achieved.

Peer review

The present manuscript deals with an interesting epidemiologic data, and the topic is also interesting.

REFERENCES

1. Gasiorkowicz M, Hurie M, Russell A, Hoxie N, Vergeront J. Epidemiologic trends in infection, mortality, and transplants related to hepatitis C in Wisconsin. WMJ 2006; 105: 34-39
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35
3. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41-46
4. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
6. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3: 57-62
7. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2005; 9: 331-338
8. Report on the Global AIDS Epidemic. Available from: URL: http://www.unaids.org/en/ HIV_data/2006GlobalReport/default.asp. Accessed on 2007-10-06
9. Chung RT. Hepatitis C and B viruses: the new opportunists in HIV infection. Top HIV Med 2006; 14: 78-83
10. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9
11. Monica F, Lirussi F, Pregun I, Vasile F, Fabris L, Okolicsanyi L. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis 2006; 38: 336-340
12. Gaeta GB, Precone DF, Cozzi-Leprì A, Ciccioni P, D’Arminio Monforte A. Multiple viral infections. J Hepatol 2006; 44: S108-S113
13. Chandra M, Khaja MN, Farees N, Poduri CD, Hussain MM, Aejaz Habeeb M, Habibullah CM. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. Trop Gastroenterol 2003; 24: 193-195
14. Chowdhury A, Santra A, Chaudhuri S, Dhalik GK, Chaudhuri S, Maity SG, Naik TN, Bhattacharya SK, Mazumder DN. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003; 37: 802-809
15. Rivera-López MR, Zavala-Méndez C, Arenas-Esqueda A. [Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors] Gac Med Mex 2004; 140: 657-660
16. Carreto-Vélez MA, Carrada-Braovo T, Martínez-Magdaleno A. [Seroprevalence of HBV, HCV, and HIV among blood donors in Irapuato, Mexico] Salud Publica Mex 2003; 45 Supp 5: S690-S693
17. Silva LK, Silva MB, Rodart JF, Lopes CB, Costa FQ, Melo ME, Gusmão E, Reis MG. Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil. Braz J Med Biol Res 2006; 39: 595-602
18. Soriano V, Barreiro P, Nuñez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815-818
19. Gunduz T, Mumcuoglu I, Güray M. Evaluation of hepatitis B surface antigen, anti-hepatitis C virus and anti-human immunodeficiency virus antibodies and syphilis seropositivity in blood donors: six years' seropositivity. J Clin Pharmacol Res 2005; 25: 155-158
20. National AIDS Control Organization (NACO). HIV/AIDS epidemiological Surveillance & Estimation report for the year 2005. Available from: URL: http://www.nacoonline.org/...
Anbazhagan GK et al. Seroprevalence of HCV, HBV and HIV among liver disease patients

33 Shire NJ, Sherman KE. Management of HBV/HIV-coinfected Patients. *Semin Liver Dis* 2005; 25 Suppl I: 48-57
34 Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. *Clin Infect Dis* 2003; 36: 79-85
35 Bhattacharya S, Badrinath S, Hamide A, Sujatha S. Co-infection with hepatitis C virus and human immunodeficiency virus among patients with sexually transmitted diseases in Pondicherry, South India. *Indian J Pathol Microbiol* 2003; 46: 495-497
36 Hussain T, Kulshreshtha KK, Sinha S, Yadav VS, Kotaich VM. HIV, HBV, HCV, and syphilis co-infections among patients attending the STD clinics of district hospitals in Northern India. *Int J Infect Dis* 2006; 10: 358-363
37 Gupta S, Singh S. Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients. *World J Gastroenterol* 2006; 12: 6879-6883
38 Poudel KC, Jimba M, Okumura J, Wakai S. Emerging co-infection of HIV and hepatitis B virus in far western Nepal. *Trop Doct* 2006; 36: 185-187
39 Chandra M, Khaja MN, Farees N, Poduri CD, Hussain MM, Aejaz Habeeb M, Habibullah CM. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. *Trop Gastroenterol* 2003; 24: 193-195
40 Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. *J Infect Dis* 2003; 188: 1815-1819
41 O’Leary JG, Chung RT. Management of hepatitis C virus coinfection in HIV-infected persons. *AIDS Read* 2006; 16: 313-316, 318-320
42 Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggiun K, Piffaretti JC, Hirschel B, Janin P, Francoli P, Fepp M, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000; 356: 1800-1805
43 Sulikowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. *JAMA* 2002; 288: 199-206
44 Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV co-infection, and outcomes following highly active antiretroviral therapy. *HIV Med* 2003; 4: 241-249
45 Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. *Clin Infect Dis* 2004; 39: 1507-1513
46 Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Panuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. *AIDS* 2004; 18: 1169-1177
47 Rockstroh J, Konopnicki D, Soriano V, Krik O, Antunes F, Keysz B, Tural C, Witt SD, Mocroft A, Lundgren J. Hepatitis B and hepatitis C in the EuroSIDA Cohort: Prevalence and Effect on Mortality, AIDS Progression and Response to HAART. Eleventh conference on retroviruses and opportunistic infections 2004; abs 799
48 Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. *J Acquir Immune Defic Syndr* 2003; 34 Suppl 1: S59-S65
49 Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. *Am J Gastroenterol* 2005; 100: 2338-2354
50 Tankhiwale SS, Khadase RK, Jalgooankar SV. Seroprevalence of anti-HCV and hepatitis B surface antigen in HIV infected patients. *Ind J Med Microbial* 2003; 21: 268-270

S- Editor Zhang HN   L- Editor Hughes D   E- Editor Liu N